Measles vaccination

Abstract

Prevention of measles poses different problems in developed and developing countries. In developed countries the risk of late complications following the use of live vaccine should be further evaluated; additional attempst might also be made to create new types of inactivated vaccine. In developing countries the introduction of live measles vaccine should be given high priority. The main problems in developing areas appear to be ones relating to vaccine stability, distribution, and cost (Au)